Click on image to view larger version.

Figure 3 Kaplan-Meier Curves of the Study's Clinical End Points

No difference in overall mortality was found between the study groups (A). A trend for lower incidence of myocardial infarctions was seen in the paclitaxel-eluting stent (PES) group (B). The incidence of target lesion revascularization (C) and of target vessel failure (D), composite end point of cardiac death, myocardial infarction, and target vessel revascularization, was significantly lower in the PES group than the bare-metal stent (BMS) group.